Table 2. Pathways significantly enriched in genes changing expression after 6 h treatment with 15 nM bafilomycin.
| Ingenuity Canonical Pathways | -log p value | Ratio | Down | No change or Not present | Up | Molecules |
| Biosynthesis of Steroids | 12.40 | 0.09 | 0/128 | 117/128 | 11/128 | FDPS, MVK, SC5DL, FDFT1, SQLE, EBP, IDI1, DHCR7, HMGCR, LSS, MVD |
| Glycolysis & Gluconeogenesis | 4.10 | 0.06 | 0/142 | 134/142 | 8/142 | GNE, PGM1, ALDOA, ALDOC, PGK1, ENO2, ACSS2, HK2 |
| Fructose & Mannose Metabolism | 3.72 | 0.04 | 0/145 | 139/145 | 6/145 | GNE, PFKFB3, ALDOA, ALDOC, PFKFB4, HK2 |
| TR/RXR Activation | 3.64 | 0.07 | 1/97 | 90/97 | 6/97 | SLC2A1, SLC16A3, PIK3C2A, LDLR, DIO2, SREBF2, FASN |
| Inositol Metabolism | 3.61 | 0.07 | 0/98 | 91/98 | 7/98 | FADS1, ALDOA, DHCR24, ALDOC, RDH11, SC4MOL, ERO1L |
| HIF1α Signaling | 3.19 | 0.06 | 1/108 | 101/108 | 6/108 | EGLN1, SLC2A1, VEGFA, EGLN3, SLC2A3, PIK3C2A, EDN1 |
| AMPK Signaling | 2.56 | 0.04 | 0/165 | 158/165 | 7/165 | PFKFB3, IRS2, PIK3C2A, HMGCR, PFKFB4, AK3L1, FASN |
| RCC Signaling | 2.54 | 0.07 | 0/72 | 67/72 | 5/72 | SLC2A1, VEGFA, EGLN3, MAP2K1, PIK3C2A |
| Ovarian Cancer Signaling | 2.04 | 0.04 | 1/135 | 129/135 | 5/135 | PTGS2, VEGFA, FZD8, MAP2K1, PIK3C2A, EDN1 |
| IGF-1 Signaling | 1.99 | 0.05 | 1/100 | 95/100 | 4/100 | GRB10, IRS2, MAP2K1, PIK3C2A, CYR61 |
Genes changing significantly in duplicate experiments were analyzed with Ingenuity Pathways Analysis software to identify pathways in which a statistically significant number of genes were changed. Only pathways with a –log p value greater than 2 by Fisher's exact T-test are shown. The “ratio” is the fraction of total genes assigned to the pathway that changed expression.